Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

Trial Profile

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FIELD Study Repeat
  • Sponsors LEO Pharma
  • Most Recent Events

    • 15 Oct 2015 Primary endpoint has been met.
    • 15 Oct 2015 Results published in the British Journal of Dermatology
    • 24 Mar 2015 Follow-up results presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top